980 related articles for article (PubMed ID: 25916739)
21. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
Wilkinson JD; Williamson EM
J Dermatol Sci; 2007 Feb; 45(2):87-92. PubMed ID: 17157480
[TBL] [Abstract][Full Text] [Related]
23. Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors.
Yang Y; Vyawahare R; Lewis-Bakker M; Clarke HA; Wong AHC; Kotra LP
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751516
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol.
Romano B; Borrelli F; Pagano E; Cascio MG; Pertwee RG; Izzo AA
Phytomedicine; 2014 Apr; 21(5):631-9. PubMed ID: 24373545
[TBL] [Abstract][Full Text] [Related]
25. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF
J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157
[TBL] [Abstract][Full Text] [Related]
26.
Pellati F; Borgonetti V; Brighenti V; Biagi M; Benvenuti S; Corsi L
Biomed Res Int; 2018; 2018():1691428. PubMed ID: 30627539
[TBL] [Abstract][Full Text] [Related]
27. The neurobiology and evolution of cannabinoid signalling.
Elphick MR; Egertová M
Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
[TBL] [Abstract][Full Text] [Related]
28. Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons.
Straiker A; Dvorakova M; Zimmowitch A; Mackie K
Mol Pharmacol; 2018 Jul; 94(1):743-748. PubMed ID: 29669714
[TBL] [Abstract][Full Text] [Related]
29. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
Castaneto MS; Gorelick DA; Desrosiers NA; Hartman RL; Pirard S; Huestis MA
Drug Alcohol Depend; 2014 Nov; 144():12-41. PubMed ID: 25220897
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of cannabinoids in CNS disease.
Croxford JL
CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective.
Karst M; Wippermann S
Expert Opin Investig Drugs; 2009 Feb; 18(2):125-33. PubMed ID: 19236260
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis.
Ribeiro R; Yu F; Wen J; Vana A; Zhang Y
Neuroscience; 2013 Dec; 254():427-42. PubMed ID: 24036373
[TBL] [Abstract][Full Text] [Related]
33. Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function.
Cabral GA; Rogers TJ; Lichtman AH
J Neuroimmune Pharmacol; 2015 Jun; 10(2):193-203. PubMed ID: 26054900
[TBL] [Abstract][Full Text] [Related]
34. Homology modeling of cannabinoid receptors: discovery of cannabinoid analogues for therapeutic use.
Chang CE; Ai R; Gutierrez M; Marsella MJ
Methods Mol Biol; 2012; 819():595-613. PubMed ID: 22183560
[TBL] [Abstract][Full Text] [Related]
35. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
Roser P; Vollenweider FX; Kawohl W
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784
[TBL] [Abstract][Full Text] [Related]
36. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells.
Greenhough A; Patsos HA; Williams AC; Paraskeva C
Int J Cancer; 2007 Nov; 121(10):2172-80. PubMed ID: 17583570
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.
Haustein M; Ramer R; Linnebacher M; Manda K; Hinz B
Biochem Pharmacol; 2014 Nov; 92(2):312-25. PubMed ID: 25069049
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoids and the expanded endocannabinoid system in neurological disorders.
Cristino L; Bisogno T; Di Marzo V
Nat Rev Neurol; 2020 Jan; 16(1):9-29. PubMed ID: 31831863
[TBL] [Abstract][Full Text] [Related]
40. Cannabis in cancer care.
Abrams DI; Guzman M
Clin Pharmacol Ther; 2015 Jun; 97(6):575-86. PubMed ID: 25777363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
